Resistance mutation info of target
| Target General Information | |||||
|---|---|---|---|---|---|
| Target ID | T89055 | ||||
| Target Name | Dual specificity mitogen-activated protein kinase kinase 2 (MAP2K2) | Target Info | |||
| Gene Name | MAP2K2 | ||||
| Species | Homo sapiens | ||||
| Uniprot ID | MP2K2_HUMAN | ||||
| Sequence | MLARRKPVLPALTINPTIAEGPSPTSEGASEANLVDLQKKLEELELDEQQKKRLEAFLTQ KAKVGELKDDDFERISELGAGNGGVVTKVQHRPSGLIMARKLIHLEIKPAIRNQIIRELQ VLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKEAKRIPEEILGKVSIAVLRG LAYLREKHQIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMAPERLQ GTHYSVQSDIWSMGLSLVELAVGRYPIPPPDAKELEAIFGRPVVDGEEGEPHSISPRPRP PGRPVSGHGMDSRPAMAIFELLDYIVNEPPPKLPNGVFTPDFQEFVNKCLIKNPAERADL KMLTNHTFIKRSEVEEVDFAGWLCKTLRLNQPGTPTRTAV [Homo sapiens] |
||||
| Drug Resistance Mutation and Corresponding Drugs | |||||
| Mutation Info | Missense: C125S | ||||
| Mutation Info | Missense: E207K | ||||
| Mutation Info | Missense: F57C | ||||
| Mutation Info | Missense: L46F | ||||
| Mutation Info | Missense: N126D | ||||
| Mutation Info | Missense: Q60P | ||||
| Mutation Info | Missense: V215E | ||||
| Mutation Info | Missense: V35M | ||||
| Reference | |||||
| Ref 555849 | ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol Cancer Ther. 2012 May;11(5):1143-54. doi: 10.1158/1535-7163.MCT-11-1010. Epub 2012 Mar 8. | ||||
| Ref 555981 | The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 2014 Jan;4(1):94-109. doi: 10.1158/2159-8290.CD-13-0617. Epub 2013 Nov 21. | ||||
| Ref 555982 | MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 2014 Jan;4(1):61-8. doi: 10.1158/2159-8290.CD-13-0631. Epub 2013 Nov 21. | ||||
| Ref 555991 | BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res. 2014 Apr 1;20(7):1965-77. doi: 10.1158/1078-0432.CCR-13-3122. Epub 2014 Jan 24. | ||||